Further reports from 13th Conference on Retroviruses and Opportunistic Infections (CROI)

HIV Treat Bull - Vol. 7, No. 5, May 2006

Earlier reports in the March and April issues of HTB, covered pipeline ARVs; treatment strategies including treatment interruptions; pregnancy and mother-to-child transmission; metabolic complications; primary HIV infection; drug interactions and epidemiology.

Further reports in this issue of HTB include studies on resource-limited settings, pregnancy, paediatrics and transmission:

• Regimen durability and toxicity in 36-month follow up on ART in Khayelitsha, South AfricaRegimen durability and toxicity in 36-month follow up on ART in Khayelitsha, South Africa
• Adults in resource-limited settings are most likely to experience an HIV-associated Illness in the first three months from initiating therapy
• Causes of death in adults receiving ARV therapy in Senegal
• Rapid scale-up of treatment in Zambia delivered at primary health level
• The effect of HIV subtype on disease progression in Rakai, Uganda
• Genital tract pharmacokinetics of ten antiretroviral drugs in HIV-positive women
• Initiation of ART leads to a rapid decline in cervical and vaginal HIV-1 RNA
• Effect of HSV-2 treatment on HIV-1 genital shedding and plasma viral load
• Once-daily FTC, ddI, and efavirenz in children and adolescents
• Simplified triple NRTI regimen effective in vertically infected children: two years follow-up
• Long-term clinical and biological outcomes in children vertically infected with HIV
• Prospective follow up of children with lipodystrophy
• Tuberculosis in HIV-infected children often missed from incidence data: the influence of HAART on paediatric TB
• Nevirapine pharmacokinetics with infant prophylaxis
• Prevention of rectal transmission of SIV in macaques using FTC with tenofovir: FTC has independent protective effect even as monotherapy
• K65R frequently emerges within 1-6 weeks of tenofovir monotherapy in macaques
• A genome armed against HIV
• Circumcision: a surprising benefit from an unkind cut
• Topical microbicides: the real front line of HIV prevention

CROI provides some of the best support for people unable to attend the meeting. Abstracts are online already, and are searchable by subject or author. Webcasts of the plenary talks, and this year, for the many oral scientific presentations, are also online, where they can be viewed, including slides, or downloaded as an .mpg audio file.

The 13th Conference on Retroviruses and Opportunistic Infections

2008-03-10
IB060705-10

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.